DOCKET NO.: CELL-0316 PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Mark Ian Christie, Richard James Mead, Martyn Kim Robinson, Stephen Edward

Rapecki Confirmation No.: Not yet assigned

Application No.: 10/580,164 Group Art Unit: Not yet assigned

International Serial No.: International Filing Date: November 16,

PCT/GB2004/004850 2004

Filing Date: November 16, 2004 Examiner: Not Yet Assigned

For: Method For The Treatment Of Multiple Sclerosis By Inhibiting IL-17 Activity

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
$\boxtimes$	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendment, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing is supported in the application, as filed, at page 24. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

DOCF	KET NO.: CELL-0316	2 -	<b>PATENT</b>
	I hereby state that the substitute cop accordance with 37 CFR §1.825(b), is	-	
	I hereby state that the substitute copaccordance with 37 CFR §1.825(d), co	•	
Date:	May 23, 2007	/David A. Cherry/ David A. Cherry Registration No. 35,099	

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2007 WW